Outcome of s60 appeal for Nasodine and next steps
Filed with ASX · · 2 pages · English
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Firebrick starts Phase 3 common cold trial of Nasodine
- March 2022 Quarterly Activity Report & Appendix 4C
- Firebrick starts COVID-19 trial of Nasodine
- 31 December Interim Financial Report & Appendix 4D
Later from Firebrick Pharma
- June 2022 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Annual Report
- September 2022 Quarterly Activity Report & Appendix 4C
- Firebrick Receives $1.08m R&D Tax Incentive
- Nasodine Composition Patent Accepted in Australia
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma